The collaborative research platform GATE is hosting its second Advanced Therapies and Tissue Engineering Annual Meeting on 17 March in Ghent. The GATE meeting brings academia and industry together to discuss next generation gene, cell and tissue therapies.

Researchers from the GATE platform – a consortium of UGent, UZ Gent, imec and VIB – will present breakthrough research in gene and cell therapy and regenerative medicine. Next to scientific and technological innovation, the event will highlight academic-industry partnerships that have successfully advanced gene and cell therapy programs in the clinic. Stakeholders will be invited to provide the latest insights in the rapidly evolving ATMP landscape in Ghent, Belgium and beyond.

GATE welcome principal investigators, clinicians and senior postdocs from academia as well as industry delegates, policymakers and life science start-ups to attend the event. Sponsorship opportunities are also available.

The half-day program includes:

• mRNA vaccine development involving successful partnerships with biotech
• Optogenetic gene therapy for epilepsy
• Innovation in CAR-T cell production, evaluation and manufacturing
• Clinical trials for gene and cell therapy

The on-site format provides plenty of opportunities to learn, connect and network with scientists, clinicians, industry innovators and policymakers in the exciting field of ATMP. The early bird deadline to register for the meeting is 17 February.